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Background and purpose: Cancer is a leading cause of death worldwide. 
Artemisinin (ARS) and its derivatives are extremely effective against malarial 
infections and have also shown good activity against tumouric cells, with the greatest 
activity reported against leukaemia and colon cancer cell lines. The current study 
aimed to investigate the antitumour activities and underlying mechanisms of action of 
novel derivatives of dihydroartemisinin (DHA) designed to target DNA (such as 
LLP246, SL2935) were evaluated against cultured HT29-AK (colon cancer cells) and 
HL-60 (leukaemia cells) cell lines.  The activity of newly synthesised tetraoxane 
dimers (RKA152M, RKA153, RKA154, RKA155, RKA157 and RKA160) were also 
evaluated against the cells.  
Methods: The cancer cells were incubated with the test compounds and assessed 
for cytotoxicity by MTT assay and cellular levels of sTfR by ELISA. The effects of 
drug treatment on apoptosis were evaluated by measuring levels of cleaved 
caspase-3, P-AKT and survivin by flow cytometric analyses and ELISA, respectively. 
Their effects on DNA fragmentation was assessed by gel electrophoresis and a 
scratch assay backed by trypan blue dye exclusion were used to evaluate the effects 
of the lead compounds on cell migration/wound healing.  
Key results: The test compounds showed potent cytotoxic effects against HT29-AK 
and HL-60 cells. LLP246 showed ~13.7 fold greater activity than DHA (IC50 of 
4.47±0.39 µM vs 61.39±2.86 µM). Among the tetraoxane dimers, RKA160 (IC50 of 
22.85±4.36 µM) displayed ~2.7 fold greater activity than DHA against HT29-AK cells. 
The tetraoxane dimers showed less cytotoxicity against HL-60 cells as compared to 
DHA (IC50 of 0.39±0.10 µM). There were measurable levels of sTfR in the cells, but 
the effects of the drugs were variable. Drug treatment caused increased activity of 
cleaved caspase-3 in the cell, P-AKT, DNA fragmentation, but decreased cellular 
survivin levels in the cells. All the test compounds showed a concentration-
dependent inhibition of cell migration/wound healing supported by a concentration-
dependent increase in dead cells.  
Conclusions and Implications: Data from these studies suggest that the 
cytotoxicity of the test compounds is may be mediated by an iron-dependent 
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mechanism, stemming from the identification of sTfR in the cells. The agents caused 
apoptosis by an increase in cellular levels of cleaved caspase-3 and decreased 
survivin concentrations. A potent inhibitory activity against the capacity of the wound 
to heal was measured. Overall, these agents may have utility (alone or in 

















                                                                               Introduction 
1.1. Cancer is a scourge of man: Cancer is a leading cause of death worldwide.                                                                                                                                                                                                                                                                                                                                                                           
As can be seen in table 1, in 2011, it is estimated that lung cancer accounted for 
1.38-1.61 million (12.7%-18.2% of the total) deaths; breast cancer, 1.38 million 
(10.9%); colorectal cancer, 1.23 million (9.7%); stomach, 0.74 million (9.7%) and 
liver cancers, 0.69 million (9.2%) (Jemal et al., 2011). The incidence of malignancy is 
increasing globally and it is estimated to reach 400,060 cases by 2015 and 530,371 
cases in the next twenty years (Ferlay et al., 2010).  
Table 1: Percentage of deaths caused different types of cancers in 2011.  
Type of cancer Percentage of deaths (%) in 2011 
Lung cancer 12.7%-18.2% 
Breast cancer 10.9% 
Colorectal cancer 9.7% 
Stomach cancer 9.7% 
Liver cancer 9.2% 
 
Some chemotherapeutic agents are not fully effective and are limited due to drug 
resistance, unfavourable side effects, such as hypotrophy, leukopenia or stomatitis 
(Efferth, 2006; Ozben, 2006; Brown et al., 2007; Jhawer et al., 2008; Shahrokni et 
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al., 2009; Raschi et al., 2010; Cheung et al., 2010; Liu et al., 2010) and many of the 
treatments are expensive. There is evidence that 5-Fluorouracil and its oral pro-drug 
capecitabine are used in treatment of a number of solid cancers including colorectal 
cancer, but exhibit side effects such as leukopenia, diarrhoea, stomatitis, nausea, 
vomiting and alopecia. Hand-foot syndrome is also a relatively common side effect of 
5-Flourouracil (Shahrokni et al., 2009). Moreover, drug-induced cardio-toxicity is 
emerging, with higher than expected incidence of cardiac dysfunction occurring in 
patients treated with a combination of old and new chemotherapeutics such as  
doxorubicin and trastuzumab (Raschi et al., 2010). There are a number of cytotoxic 
drugs that are most frequently associated with drug-resistance e.g. paclitaxel, 
vinorelbine, doxorubicin, methotrexate, dactinomycin and metomycin (Ozben, 2006).  
To identify chemotherapeutic agents with improved profiles over existing ones, some 
of the current research is focussed on harnessing the chemotherapeutic potential of 
natural products (Efferth, 2005; Cheung et al., 2010; Lee et al., 2010; Hussain et al., 
2011). Traditional Chinese Medicine (TCM) has been reported to benefit one fifth of 
the world’s population in treating many diseases and its acceptance as a real healing 
option by the west is of increasing interest (Parekh et al., 2009). It has been reported 
that there are a number of TCMs, such as Scutellaria baicalensis commonly referred 
to as ‘Golden root’, Takrisodokyeum (TRSDY)- comprising 12 herbs in various 
proportions which have shown promising activities against various cancer cell lines, 
such as PC-3 (prostate cancer), DU145 (prostate cancer), HL60, KML-562 (chronic 
myloid leukaemia), HeLa (cervical cancer) and HO-8910 (ovarian cancer) cell lines 
(Chan et al., 2000; Li et al., 2000; Chen, Zhou and Fan, 2003; Chi et al., 2003; 
Efferth et al., 2003; Kwon et al., 2003; Tan and Vanitha, 2004; Yu et al., 2006; Zhou 
et al., 2007). These herbs contain flavonoid-rich elements which are thought to 
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impart anti-inflammatory, antibacterial, anti-neoplastic, pro-apoptotic, anti-
proliferative and anti-angiogenic effects (Igney and Krammer, 2002; Po et al., 2002; 
Nelson and Montgomery, 2003; Powell et al., 2003; Parekh et al., 2009; Gravett et 
al., 2011; Soomro et al., 2011). It has been reported that Scutellaria baicalensi 
causes simultaneous inhibition of Cox-2 (pro-inflammatory marker) and 12-
lipooxygenase (tumour cell proliferatory marker) which result in both reduced 
inflammation and tumorigenesis (Pidgeon et al., 2002; Burnett et al., 2007). There is 
also evidence that Scutellaria baicalensi acts against cell proliferation in PC-3 and 
DU145 cells, causing cell cycle arrest (at G0-G1) while also inducing apoptosis as  
confirmed detection of caspase-3 (Chan et al., 2000). Further evidence of TCMs 
acting via caspase-3 activation was demonstrated by Kwon and colleagues showing 
that treatment of these cells with TRSDY caused caspase-3-induced cytotoxicity 
(Kwon et al., 2003), which causes DNA fragmentation, chromatin condensation and 
plasma membrane blebbing (Sahara et al., 1999; Sebbagh et al., 2001). Kwon and 
colleagues supported their conclusions by using a caspase-3 inhibitor in their assay 
which resulted in lack of detectable capsase-3 production and the downstream 
cleavage of cellular death substrates was also absent (Kwon et al., 2006). 
Phytochemicals have long been used as ‘lead compounds’ to generate test 
compounds with better pharmacokinetic profiles and reduced toxicity in vivo. For 
example, the artemisinins are potent chemotherapeutic agents against malaria 
infections and have also shown good cytotoxic effects and anti-angiogenic properties 
(Efferth et al., 2001; Efferth et al., 2002; Chen et al., 2004; Parekh et al., 2009). It 
has been reported that TCM often possess quite distinct and specialised modes of 
action and consequently tumours that are normally resistant to conventional 
chemotherapy may show some susceptibility to TCM therapy (Shi and Tian, 2006). 
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There is evidence that herbal compounds such as paclitaxel and its derivatives 
suppress microtubule depolarization, thus terminating cell mitosis (Kaye, 1999). As a 
result, these and compounds including harringtonine (Cephalotaxus hainanensis) 
and camptothecin (Camptotheca acuminate) with similar mechanisms of action are 
already commonly used in the clinic as anticancer agents for a variety of cancers 
(Wang and Yang, 2001). 
1.2. The artemisinins as antimalarials and their mode of action: Artemisinin also 
known as Qinghaosu, was isolated in 1971 from sweet wormwood (Artemisia 
annua), which has been used as a Chinese herbal medicine for over 2000 years 
(Singh and Lai, 2001). ARS and its semi- and synthetic derivatives such as DHA, 
artesunate (ART) and artemether (figure 1) are extremely effective against malarial 
infections (O’Neill, Barton and Ward, 2010; Kano, 2010; Krungkrai et al., 2010; 
Gravett et al., 2011; Soomro et al., 2011; Wu et al., 2011). It has been reported that 
the compounds have been effective against chloroquine and sulfadoxine-
pyrimethamine resistant and sensitive Plasmodium falciparum, the causative agent 
of severe malaria infections (Kano, 2010), although there is evidence of emerging 
resistance against these agents in South East Asia (Noedl, Socheat and Satimai, 
2009). ART is also found effective against Plasmodium vivax, showing broad 
specificity and rapid onset of action against early blood forms of the parasites 
(Efferth et al., 2004; O’Neill, Barton and Ward, 2010; Wu et al., 2011). Figure 1 



































Artemisinin Dihydroartemisinin Derivatives      R
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Artesunate   -OCOCH2CH2COO-       
Figure 1: Chemical structure of artemisinin and some of its semi-synthetic derivatives.                      
ARS is a tetracyclic 1,2,4-trioxane sequesterpene lactone containing an 
endoperoxide bridge, which is essential for its activity (Efferth et al., 2004; Mercer et 
al., 2007; Nakase et al., 2008; O’Neill, Barton and Ward, 2010; Alessandro et al., 
2011). Briefly, the antimalarial mode of action of ARS is based upon the formation of 
C-centred unstable free radicals [Fe(IV)=O], by reductive cleavage of the 1,2,4-
trioxane, catalysed by the Fe (II) haem, generated as a by-product of the 
haemoglobin catabolism (Singh and Lai, 2001). The parasite degrades haemoglobin 
in its food vacuole, producing free haem which reacts with the endoperoxides and 
generates toxic reactive species (Robert et al., 2001). The resulting free radical 
intermediate may then kill the parasite by alkylating essential malarial proteins, one 
of which is the translationally controlled tumour protein (TCTP)   (Meshnick, 2002; 
Efferth et al., 2004; Mercer et al., 2007; Hommel, 2008; Nakase et al., 2008; Jones 
et al., 2009; Raghavamenon et al., 2011). It has been reported that malarial 
parasites are rich in haemin; ARS’s reactivity towards haemin may explain its 
selective toxicity to malarial parasites (Meshnick et al., 1991) as iron chelators 
antagonise the antimalarial activity of the ARS (Eckstein-Ludwig et al., 2003; 
Weinberg and Moon, 2009). These agents have good antimalarial properties, reduce 
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parasite clearance rapidly, show limited significant toxicity, even for pregnant 
women, despite the fact that neurotoxicity was observed in animals with higher 
doses than used clinically (Robert et al., 2001). However, there is worrying evidence 
of emerging resistance against the agents in SE Asia (Noedl, 2009; Noedl et al., 
2009; Noedl et al., 2010). 
1.3. The artemisinins as antitumour agents and their mode of action: Since the 
mid 1990s, subsequent studies have observed ARS and its analogues (1,2,4-
trioxanes) to possess antitumor, antiproliferative and with some derivatives such as 
deoxoartemisinin amide trimer eliciting antiangiogenic properties (Moore et al., 1995; 
Nakase et al., 2008; Oh et al., 2009; Zhang et al., 2010), against many cancer cell 
lines including colorectal (HT29-AK, HCT-116 and SW-480), leukaemia (Jurkat and 
HL-60),  hepatoma (HepG2 and Huh-7), lung (SPC-A-1), prostate (C4-2 and 
LNCaP), breast (MDA-MB-231 and MCF-7), endothelial (HMEC-1), osteosarcoma 
and pancreatic (BxPc3-RFP) cancer cells (Moore et al., 1995; Posner et al., 1997; 
Beekman et al., 1997; Beekman et al., 1998; Mercer et al., 2007; Parekh et al., 2009; 
Morrissey et al., 2010; Aung et al., 2011). Unfortunately, many of the agents are 
effective against tumour cells within the micromolar range as opposed to the 
nanomolar range seen against Plasmodium parasites (Efferth, 2006), but it is hoped 
that via rational drug design this range can be reduced. This may be achieved by 
designing and synthesising new compounds with better pharmacokinetic profile, so 
that, they may represent alternatives to the currently used artemisinin derivatives. A 
collaborative research effort in own lab led to the development and evaluation of 
1,2,4-trioxane-acridine hybrids which produced 2-4 fold enhanced cytotoxicity activity 
against a variety of cancer cell types including leukaemia (HL-60), colon (HT29-AK) 
and breast (MDA-MB-231 and MCF-7) compared to parent 1,2,4-trioxane. They have 
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been shown to induce cell death by apoptosis assessed by flow cytometric 
measurements of mitochondrial membrane depolarisation, DNA degradation and 
Western blot analysis of caspase-3 activation and to covalently bind to their 
intraparasitic cellular targets in the presence of iron (Jones et al., 2009). 
It has been reported that ARS and its derivatives are effective against cervical 
disorders associated with papillomavirus infection, such as cervical cancer and 
cervical dysplasia and is being used in vitro and in vivo against premalignant and 
malignant cells. In this study, ARS compounds were used against HPV-infected or 
trasformed cells and canine oral papillomavirus. In in vitro study, DHA-induced cell 
death involved activation of the mitochondrial caspase pathway with resultant 
apoptosis and in vivo study reported that tumour-negative dogs developed 
antibodies against the viral L1 capsid protein, suggesting that DHA had inhibited 
tumour growth (Disbrow et al., 2005). It has been investigated that DHA analogues 
inhibited cell proliferation and tube formation of human umbilical vein endothelial 
cells (HUVECs) in a time- and dose-dependent manner, which resulted in inhibition 
of tumour growth in vitro and in vivo (Noori and Hassan, 2011). Recently, artemisone 
(ATM), a novel derivative of ARS was found to be more effective against cancer cells 
when used alone or in combination with other chemotherapeutic agents such as 
oxaliptin, gemcitabine and thalidomide (Gravett et al., 2011). In a recent study, 10-
substituted triazolyl ARS compounds were synthesized and have been observed to 
strongly inhibit the growth of cancer cell lines, such as, DLD-1(human colon 
carcinoma cells), U-87 (human primary glioblastoma cells), Hela, SiHa (cervical 
cancer cell line), A172 (human glioblastoma cell line) and B16 (mouse melanoma 
cell line) (Oh et al., 2010).  
The postulated antitumor mechanism is similar to the antimalarial mechanism of 
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ARS (Li and Zhou, 2007). Rapid proliferation is a basic feature of malignant cells, 
which requires high intracellular iron acts as a cofactor of DNA metabolism and 
continued cell proliferation (Mercer et al., 2007; Oh et al., 2009; Zhang et al., 2010; 
O’Neill, Barton and Ward, 2010). Clearly, for the cells to utilise iron, they must 
express the receptors (transferrin receptors (TfRs)] to take it up (Beguin, 1992; 
Harford, 1994). To this end, TfR binds and internalises di-ferric transferrin to the 
cytosol. TfR expression is increased to facilitate iron uptake (Rao et al., 1985; 
Mullner and Kuhn, 1988; Koeller et al., 1989) and proteolysis of TfR leads to the 
formation of soluble transferrin receptor (sTfR) (Shih et al., 1990; Baynes et al., 
1993) which can be measured. Measurement of sTfR is especially valuable as an 
indicator of iron deficiency in individuals with malignancy, inflammatory diseases and 
infections (Ferguson et al., 1992; Erslev and Besarab, 1995). Thus a relationship has 
been exists between total TfR and sTfR and the concentration of sTfR has been 
demonstrated to be an indirect measure of total TfR (Beguin et al., 1988). It has 
been reported that most of the cancer cells possess a high cell surface concentration 
of transferrin receptors (TfRs). For example, breast cancer cells have almost 5-15 
times more TfRs compared to normal cells and hence have high rates of iron intake 
(Singh and Lai, 2001). The aggressiveness of tumour cells has also been shown to 
be positively correlated to the high surface expression of TfRs (Efferth, 2005; Singh 
and Lai, 2006; Cheung et al., 2010; Xie et al., 2010). Interestingly, elevated iron 
levels allow the selective toxicity of ARS towards the cancer cells (Beekman et al., 
1998; Singh and Lai, 2005). Just as in malarial parasites, ARS becomes cytotoxic in 
the presence of ferrous iron which catalyses the reductive cleavage of the 
endoperoxide bridge leading to the formation of carbon-centred radicals, which 
cause cell death via macromolecular damage (Singh and Lai, 2006; O’Neill, Barton 
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and Ward, 2010). Plasmodium TCTP represents a known target of ARS and its 
derivatives in the malarial parasites. The microarray-based mRNA expression of 
human TCTP correlated with sensitivity to ART in tumour cells, suggesting that 
human TCTP contributes to response of tumour cells to the drug (Efferth, 2005).  
Given that iron is central to the activity of ARSs, various manipulations have been 
attempted with the view to enhance the cytotoxic effects of the test compounds. For 
example, conjugation of ARS or DHA to transferrin has been shown to increase their 
targeted delivery and cytotoxic activity against tumouric cells such as DU145 (Lai et 
al., 2005; Nakase et al., 2008; Oh et al., 2009; Xie et al., 2010). The selective toxicity 
of the ARSs has also been demonstrated to be approximately 100 times more potent 
in killing human leukemia cells than normal lymphocytes (Singh and Lai, 2006), with 
the selectivity stemming from the differential levels of iron in the two cancer cell 
types. In vitro studies have verified the potent activity of ARS-transferrin conjugate 
against Molt-4-lymphoblastoid cells (Singh and Lai, 2001), while DHA-transferrin 
conjugate showed approximately 172 times more cytotoxicity against MCF-7 cells 
than DHA (Oh et al., 2009; Xie et al., 2010). The role of iron in the cytotoxicity of 
ARSs was further demonstrated by the observation that deferoxamine (an iron 
chelator) attenuated their cytotoxic effects (Mercer et al., 2007; Huang et al., 2007; 
Stockwin et al., 2009; Raghavamenon et al., 2011). Furthermore, a recent study 
found that oral co-administration of ART with ferrous sulphate induced greater 
apoptosis of cancer cells compared to ART alone (Fafowora et al., 2011), suggesting 
that iron plays an important role in the cytotoxicity of ART.  
The anti-oxidant stress genes (thioredoxin, catalase, and glutathione S-transferases) 
as well as the epidermal growth factors confer resistance to ART. Moreover, it has 
been reported that cell lines over-expressing genes that confer resistance to 
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established anti-tumour drugs (MDR, MRP1, dihydrofolate reductase), were not 
cross-resistant to ART, indicating that this drug has a different target and is not 
subject to multidrug resistance (Efferth, 2005). 
1.4. Effects of artemisinins on apoptosis: There is evidence that ARS induces 
apoptosis in vitro and is lethal towards human leukemia and breast cancer cells 
(Efferth et al., 2004; Singh and Lai, 2006). Clearly, apoptosis is controlled by a range 
of complex multi-step processes that consequently lead to  the breakdown of cellular 
DNA leading to cell death (Parekh et al., 2009). One of these multi-step events in 
cancer cells includes the induction of caspase-dependent apoptotic cell death. It is 
postulated that the activation of the endoperoxide bridge leads to apoptosis by 
caspase-dependent pathways, in which ‘initiator’ caspases (caspases 8, 9 and 10) 
have the primary role of processing and activating both pro-enzymes (procaspases-
8,-9 and-10) and ‘executioner’ caspases (caspases 3, 6 and 7), which ultimately 
cause cell death (Rathmell and Thompson, 1999; Mercer et al., 2007; Parekh et al., 
2009; Ji et al., 2011; Raghavamenon et al., 2011). Some of the remaining apoptotic 
events include induction of mitochondrial endoplasmic reticulum stress, release of 
cytochrome c, induction of cell cycle arrest at Go/G1 phase and subsequent DNA 
fragmentation (Parekh et al., 2009). Indeed, there is evidence that ARS affect all 
these important processes such as apoptosis. ARS derivatives have been shown to 
induce caspase-dependent apoptotic cell death characterized by concentration- and 
time-dependent mitochondrial membrane depolarization, activation of caspase-3 and 
-7, sub- Go/G1 DNA formation and attenuation by benzyloxycarbonyl-VAD-
fluoromethyl ketone, a caspase inhibitor (Mercer et al., 2007; Shao et al., 2008; 
Parekh et al., 2009; Handrick et al., 2010; Lu et al., 2010; Zhang et al., 2010; 
Morrissey et al., 2010; Alessandro et al., 2011). Gao and colleagues have 
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demonstrated that DHA induced apoptosis in a concentration- and time-dependent 
fashion in cultured human leukemia cells and it also demonstrated an anti-leukemic 
activity in vivo through a process that involves inactivation of MEK (mitogen-
activated protein kinase)/ERK (extracellular signal-regulated protein kinase), Mcl-1 
(myloid leukaemia cell differentiation protein) down-regulation, culminating in 
cytochrome c release and caspase activation (Gao et al., 2011). Furthermore, DHA 
is well documented to cause apoptosis in microvascular endothelial cells (HMEC-1) 
via increase in caspase 3 and 7 activation (Alessandro et al., 2011), 
phosphatidylserine exposure and G2 cell cycle arrest (Ji et al., 2011). 
There are a series of signalling pathways, for example, ARF(alternative reading 
frame)/Mdm-2/p53 pathway whose activation and suppression lead to a cascade of 
intracellular events which ultimately result in cell death (Green and Evan, 2002). For 
example, the mitochondrion plays a central role in cell survival and many of the 
triggers of apoptosis are known to act in mitochondria-dependent manner (Petit et 
al., 1996; Bossy and Green, 1999; Parekh et al., 2009; Fafowora et al., 2011). DHA 
has been shown to cause apoptosis via the mitochondrial pathway, by reducing 
cellular iron influx. This is postulated to result in decreased expression of TfRs, 
which is thought to be mediated via the down-regulation of proliferating cell nuclear 
antigen (PCNA), a key regulator of DNA synthesis and repair; anti-apoptotic protein 
Bcl-2 (B-cell lymphoma 2), VEGF (vascular endothelial growth factor) and up-
regulating pro-apoptotic protein Bax (Bcl-2-associated x protein) in pancreatic cancer 
cells under normoxic, but not hypoxic conditions (Jiao et al., 2007; Zhou, Wang and 
Li, 2008; Aung et al., 2011).  
Apoptotic cells also have a major distinctive characteristic of DNA fragmentation, 
which occurs by endogenous endonucleases activation, producing 
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oligonucleosomes (Mercer et al., 2007; Jiao et al., 2007; Lu et al., 2009). It is 
postulated that the carbon-centred free radicals generated by ARS and its 
derivatives upon reductive cleavage by iron alkylates into DNA (Jeyadevan et al., 
2004) which may cause DNA fragmentation.  
Interestingly, it has been demonstrated that DHA-mediated apoptosis is correlated 
with inhibition of the PI3-kinase/AKT (phosphatidylinositol 3-kinase/serine-threonine 
protein kinase) and extracellular signal regulated kinase (ERK) survival pathway, in 
human prostate malignant cells and colorectal cancer cells (He et al., 2010). There is 
also evidence that AKT (also a protein kinase) plays a vital role in a number of cell 
signalling pathways, such as mTOR (mammalian target of rapamycin) and regulates 
pro-survival genes such as PTEN (phosphatase and tensin homologue deleted on 
chromosome 10) in many cancers (O’Gorman et al., 2000; Testa and Tsichlis, 2005; 
De Souza, Russell and Kearsley, 2009) and the effects of ARS on this molecule 
warrants investigating. 
Clearly, all cells have to control the level of apoptosis that is occurring and as such 
there are many innate pathways involving inhibitors of apoptosis, such as survivin 
which promote cell survival (Wheatley et al., 2005). Survivin is an inhibitor of 
apoptosis which is initiated by both intrinsic and extrinsic apoptotic pathways 
(Ambrosini et al., 1997; Muchmore et al., 2000; Salvesen and Duckett, 2002; Altieri, 
2003; Schimmer, 2004; Wheatley et al., 2005). Survivin suppresses cell death and 
therefore plays a vital role in cell division. There is also evidence that it plays a role 
in tumour formation and resistance to anti-cancer agents (Zaffaroni, Pennati and 
Daidone, 2005). Survivin is highly expressed in human malignancies including 
colorectal cancer and leukaemia, but rarely in healthy tissues (Tamm et al., 1998; 
Dohi et al., 2004; McNeish et al., 2005; Lu, Luo and Tao, 2007; Ryan, O'Donovan 
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and Duffy, 2009) and may act as a marker and prognostic indicator for certain 
cancers including pancreatic and colorectal cancers (Zaffaroni et al., 2005). The anti-
apoptotic effect of survivin stems from its inhibitory action on caspase 3 and 7 
(Tamm et al., 1998) and it is known to play modulate the activity of a number of 
molecules important for cell growth and survival (Dohi et al., 2004; McNeish et al., 
2005). Previous studies in 4 prostate cancer cell lines (C4-2, LNCaP, DU145 and 
PC-3) demonstrated that the ARS dimer, 2PY (at 15µM) significantly decreased the 
expression of survivin at the mRNA levels (Morrissey et al., 2010).  
1.5. Effects of artemisinins on metastasis: Metastasis and invasion are properties 
unique to malignant cells and they are a leading cause of morbidity and mortality 
(Hwang et al., 2010). The invasion of lymphnodes and blood vessels are important 
steps in metastasis which requires increased expression of matrix 
metalloproteinases (MMPs), cell-extracellular matrix (ECM) interactions, 
disconnection of intercellular adhesion and degradation of ECM (Liotta, Steeg and 
Stetler-Stevenson, 1991; Deryugina et al., 1997; Stamenkovic, 2000; Hwang et al., 
2010). MMPs have been implicated in malignancy and members of its family are 
involved in degradation of ECM (Westermarck and Kahari, 1999; Stamenkovic, 
2000; Hwang et al., 2010). The activity of MMPs is kept in check by TIMPs (tissue 
inhibitor of matrix metalloproteinases). It has been reported that inhibition of the 
expression of MPPs can be used as early targets for preventing cancer metastasis 
(Liabakk et al., 1996; Hwang et al., 2010; Wang et al., 2011). ARS has been 
reported to have inhibitory effect on invasion and metastasis of human hepatocellular 
carcinoma (HCC) cell lines (HepG2 and SMMC-7721). The test compounds inhibited 
the invasion and migration of the cells in vitro and in vivo by reducing the levels of 
MMP2 and inducing cellular levels of TIMP2 (Du et al., 2010; Weifeng et al., 2011). 
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There is evidence that DHA is also acts as an effective anti-metastatic agent, down-
regulates MMP-9 gene expression, through inhibition of PKCα (protein kinase C-
alpha)/Raf (Ras factor)/ERK (extracellular signal-regulated kinase) and JNK (C-Jun 
N-terminal kinases) phosphorylation in human fibrosarcoma HT-1080 cells (Hwang 
et al., 2010; Wang et al., 2011). 
1.6. Our Strategy – looking forward: The artemisinins have shown great promise 
as anticancer agents and may have potential clinical utility (Chen et al., 2004; 
Efferth, 2007). However, a great deal of work remains to be done on them so as to 
bring their activity against tumouric cells to those seen in P. falciparum.  Overall, the 
agents are active against tumour cells in the micromolar range as opposed to the 
nanomolar concentrations measured against P. falciparum (Efferth, 2006). In order 
to pharmacoenhance the activity of the agents, there is interest in the use of pyrrole-
based reagents to target the minor groove of DNA in a sequence-selective manner 
(Jones et al., 2009). Interestingly, it has been reported minor groove binders such as 
2,2’-dipyrrole derivatives have anti-tumour activity (Baraldi et al., 2003 and 2006; 
Zaitsev et al., 2006). Recent evidence showed that these molecues can be 
synthesised as hybrids with DHA with 2-4 fold greater against leukamia, colon and 
bvreast ceancer cells than DHA (Jones et al., 2009). Furthermore, the synthesis of 
numerous hybrids from the dipyrrole framed netropsin tethered to benzoyl nitrogen 
mustard moiety also resulted in more cytotoxic agents than the parent agents 
(Baraldi et al., 2003).  
In order to increase the stockpile of our anticancer agents, interest is growing 
towards the use of 1,2,4,5-tetraoxanes as potential antimalarial and more recently 
anticancer agents (Singh and Lai, 2001; Efferth et al., 2004; Terzic et al., 2007; 
Opsenica et al., 2008; Atheaya et al., 2008). They are purely synthetic and made 
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from readily available, cheap starting materials with identical  mode of action as the 
ARS (Wu, 2002).  
Through a collaborative research partnership with the Chemistry Department of the 
University of Liverpool, rationally designed and synthesised DHA-minor groove 
binding conjugates and a number of novel tetraoxane dimers (figure 2) with the view 
to identifying agents with activities over and above the parent artemisinins, were 
obtained. LLP246 and SL2935 were designed to incorporate metabolically stable 
1,2,4 trioxane moiety. Given that the endoperoxide bridge is essential for activity, the 
tetraoxane dimers were synthesised with the hope that they would liberate more 
biologically reactive metabolites upon reductive cleavage by cellular iron.  There is 
evidence that the highest cytotoxicity of the endoperoxides has been reported 
against human colon and leukaemia cancer cells which are most sensitive, rapidly 
proliferating cells with high expression of transferrin receptors needed for 
endocytosis-mediated iron intake (Mercer et al., 2007; Jones et al., 2009). 
Consistent with these findings, the cytotoxicity and mechanistic basis of activity of 
these agents against cultured human leukaemia (HL-60) and also colon (HT29-AK) 
cancer cell lines were evaluated.  
Aims and Objectives:  
1) To investigate the effects of the test compounds against HL-60 and HT29-AK 
cancer cells with the view to identifying lead molecules for development. 
2) To evaluate the effects of the agents on sTfR, caspase-3, survivin, DNA 
fragmentation and P-AKT in order to identify the biochemical and molecular 
basis of toxicity of the test compounds. 
[18] 
 
3) The effects of test compounds on the migration of cancer cells in a scratch 
















































































































Figure 2: Shows the chemical structures of the test compounds used in this study. A (LLP246) is a 
dihydroartemisinin-acridine hybrid and B (SL2935) is a dihydroartemisinin-dipyrrole hybrid. The tetraoxane 




                                                              Materials and methods 
2.1. Materials 
DHA was obtained from Dafra Pharma (Belgium). Hybrids of DHA (LLP246 and 
SL2935) and the tetraoxane dimers (RKA160, RKA153, RKA154, RKA155, RKA157 
and RKA152M) were supplied by Prof Paul O’Neill (Liverpool University, UK) through 
a collaborated research project. Human leukaemia cells (HL60), colon cancer cells 
(HT29-AK) and cleaved caspase-3 and P-AKT Ser 473 antibodies were obtained 
from European Collection of Cell cultures and Cell Signalling, New England Biolabs 
(Herts, UK), respectively. All media were supplied by Biosera and Invitrogen, Paisley 
(UK) and chemicals were supplied by Fisher Scientific (Leicestershire, UK). All the 
stock solutions of test compounds were created using 100% dimethyl sulfoxide 
(DMSO). The final concentration of DMSO in each incubation was less than 0.5%, 
which did not affect the viability of the cells. 
2.2. Cell culture 
HL-60 cells were grown in RPMI1640 (Roswell Park Memorial Institute 1640 
medium), supplemented with 10% FBS (fetal bovine serum). HT29-AK cells were 
cultured in EMEM (Eagle’s minimal essential medium), supplemented with 10% fetal 
bovine serum and 20 mM glutamine (Lonza, Verviers, Belgium). Both cell lines were 
incubated at 37 °C in a humidified atmosphere of 5% CO2 and subcultured after 




2.3. Trypsinisation (only for adherent HT29-AK cells) 
To detach the adherent cells at the start or end of experiments, such as the test 
compounds screening assay and at the end of some incubations e.g. cleaved 
caspase-3 activity, trypsinisation process was used. At about a cell confluency of 
70%, medium from culture flasks was aspirated and discarded. The attached cells 
were washed three times with 5 ml of sterile phosphate buffer saline (PBS) and the 
PBS discarded each time. After the final PBS wash, 1 ml of trypsin (Lonza, Verviers, 
Belgium) was added to the flask and incubated at 37 °C for about 5 minutes. Once 
the cells have detached, the trypsin was inactivated by the addition of 10-15 ml of 
MEM medium, supplemented with 10% FBS. 
2.4. Cell counting 
Before the start of any of the experiments reported here in, the cells were counted in 
order to fix the cell density in each assay. This was done using Nucleocounter 
(Chemometec, Allerod, Denmark). Briefly, 50 µl of reagent A (lysis buffer) was added 
to 50 µl of cell suspension in eppendorff and vortexed well for about 1 minute. 
Further, 50 µl of reagent B (stabilising buffer) was added to the lysed samples and 
vortexed. A small volume of the sample was then drawn into the nucleocassette 
which was preloaded with propidium iodide. The cells were then counted by loading 
the nucleocassette into cell counter socket. 
2.5. MTT Cytotoxicity assay 
Cytotoxicity of DHA, LLP246, SL2935 and RKA compounds were determined using 
the MTT cytotoxicity assay (Mosmann, 1983). The cells (1×104 cells) were seeded in 
96-well flat-bottomed micro-plates and incubated them with varying concentrations of 
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the test compounds (0-100 µM) for 24 hr (at 37°C, 5% CO2) as described previously 
(Jones et al., 2009).  After incubation, the assays were terminated by adding 20 µl of 
5 mg/ml MTT ( (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a 
yellow tetrazole) and incubated for 2 h. Then the cells were lysed by adding 100 µl of 
lysis buffer (20% sodium dodecyle sulphate in 50% dimethylformamide) and further 
incubated overnight. The optical density of the samples were then analysed at 492 
nm in a plate reader (Anthos plate reader 2001, Anthos laboratory instruments, UK).  
2.6. Data analysis to determine IC50 of the test compounds upon treatment 
In order to allow the activity of the test compounds to be evaluated, the effects of test 
compounds treatment on cell growth versus control samples were estimated using 
the following equation: 
% of control cell growth = optical density of test compound-treated samples x 100 
                                 optical density of control samples 
A plot of the percentage of cell growth compared to control against the test 
compound concentrations allows the estimation of the IC50 values using the 4 
parameter logistic analysis (Grafit, Erithacus Software; UK). IC50 is the inhibitory 
concentration that kills/inhibits 50% of the cell growth.  
2.7. Effect of test compounds treatment on sTfR 
Enzyme-Linked Immunosorbent Assays (ELISAs) were used to investigate the 
effects of the test compounds on sTfR. HT29-AK cells (5×106 cells/flask) were 
incubated for 24 h (37 °C, 5% CO2) in the absence and presence of LLP246 (4.5 µM, 
2.2 µM, 1.1 µM); SL2935 (64.8 µM, 32.4 µM, 16.2 µM) and DHA (61.4 µM, 30.7 µM, 
15.3 µM). Thereafter, the cells were collected by centrifugation following 
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trypsinisation and the cell lysates were prepared for the estimation of sTfR following 
the manufacturer’s protocols (R&D Systems, UK).  
For the determination of sTfR, 100 µl of sTfR assay diluent was added to each well, 
followed by the addition of equal volume of lysates/standard solutions. The samples 
were incubated for about 1 h at room temperature, before the wells were aspirated 
and washed three times with wash buffer. Then 100 µl of sTfR conjugate was added 
to each well and incubated for 1 h. Thereafter, the wash step was repeated, followed 
by the addition of 100 µl/well of substrate solution. The plates were incubated for 30 
minutes at room temperature, followed by the addition of stop solution (100 µl/well). 
Finally, the plates were read at 450 nm within 30 minutes and the level of sTfR 
determined from the sTfR standard curve. 
2.8. Effect of test compounds treatment on cleaved caspase-3 activity and P-
AKT phosphorylation  
A flow cytometery technique was performed in order to determine the effect of test 
compounds treatment on the activity of cleaved caspase-3 and P-AKT. HT29-AK 
cells (5×106 cells/flask) were incubated with and without LLP246 (1.1 µM, 2.2µM and 
4.5µM) and DHA (15.3 µM, 30.7 µM and 61.4µM).  
In order to investigate the effect of tetraoxane dimers on cleaved caspase-3 activity 
HL-60 cells (5×106 cells/flask) were incubated with and without RKA155 (28.2 µM, 
9.4 µM, 18.8 µM and 28.2µM); RKA160 (10.1 µM, 20.2µM and 30.3µM) and DHA 
(0.2 µM, 0.4µM and 0.6µM).  
The assays were incubated for 24 h at 37 °C, 5% CO2 before being terminated by 
centrifugation (1200 rpm, 2 minutes, room temperature). The supernatant was 
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discarded and the cell pellets were resuspended in 250 µl PBS and centrifuged 
(1200 rpm, 2 minutes). The samples were fixed in 250 µl of 6% formaldehyde (37 °C, 
10 minutes), followed by cell permeabilisation in 1 ml of 90% methanol. Thereafter, 
the samples were centrifuged (1200 rpm, 2 minutes), followed by 2 wash steps with 
200 µl of incubation buffer (0.5% BSA [bovine serum albumin] in PBS). Then the 
samples were further washed in 100 µl of incubation buffer and incubated at room 
temperature for 10 minutes. Thereafter, the samples were incubated for 1 h in 100 
µl/tube of the primary antibody (1:100 final dilution of antibody) for the pro-apoptotic 
marker cleaved caspase-3 or P-AKT antibody. The samples were centrifuged and 
the cell pellets were then washed in 200 µl of incubation buffer, followed by 
resuspension of cell pellets in 100 µl of incubation buffer and analysed on the BD 
FACS Calibur® flow cytometer on the FL-1 channel. Histograms were plotted for 
each of the groups showing the mean fluorescence for 10,000 counts.  
2.9. Effect of test compounds treatment on DNA damage  
HT29-AK cells (5×106 cells/flask) were incubated in the absence and presence of 
LLP246 (1.1 µM, 2.2µM and 4.5µM); SL2935 (16.2 µM, 32.4µM and 64.8µM) and 
DHA (15.3 µM, 30.7µM and 61.4µM).  
The flasks were incubated for 24 h at 37 °C, 5% CO2. Thereafter, the assays were 
terminated by centrifugation (8000 rpm, 10 seconds). The cell pellets were 
resuspended in 200 µl of media, ensuring each sample did not contain more than 
1×107 cells. DNA was isolated following DNA isolation protocol of QIAGEN 
(Maryland, USA). Briefly, 200 µl of a well-mixed sample was added to the capture 
column tube by gently touching the tip of micropipette to the centre of the matrix, 
followed by incubating the capture column along with sample for about 30 minutes to 
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1 h at room temperature, which allows the DNA to adsorb onto the matrix. Then 400 
µl DNA purification solution 1 was added to the capture column and further incubated 
for 1 minute at room temperature, followed by centrifugation (8000 rpm, 10 seconds). 
Thereafter, 400 µl of purification solution 1 was added to the capture column and 
incubated for 1 minute at room temperature. The collection tube was centrifuged at 
8000 rpm for 10 seconds. Then, 200 µl of DNA elution solution 2 was immediately 
added followed by centrifugation (8000 rpm, 10 seconds). A 100 µl DNA elution 
solution 2 was then added and incubated at 99 ºC for 10 minutes followed by 
centrifugation (8000 rpm, 20 seconds) to finally obtain the purified DNA.  
The DNA concentration in each sample was measured using Nano-Drop (ND-1000 
3.3 software, Labtech International, UK). DNA concentration of each sample with 
LLP246 (93.0 ng/µl, 127.9 ng/µl, 307.9 ng/µl); SL2935 (69.6 ng/µl, 136.2 ng/µl, 207.9 
ng/µl) and DHA (121.1 ng/µl, 156.6 ng/µl, 256.2 ng/µl) including control (507.0 ng/µl) 
were separated for 30 minutes on a 1.0% agarose gel stained with 2 µl of ethidium 
bromide. The samples were separated with parallel molecular marker, lamda Eco 
1301. In this experiment 507.0 ng/µl of the heat-treated control, being control 
samples treated at 95 °C for 20 minutes to serve as positive control was used. The 
samples were visualized and photographed under a UV-light in GEL-DOC. 
2.10. Effect of test compounds treatment on cellular survivin concentration 
HT29-AK cells (2×106 cells/well) were incubated for 24 h (37 °C, 5% CO2) in 6-well 
flat bottomed plates in the absence and presence of LLP246 (41.1 µM, 2.2µM and 
4.5µM); SL2935 (16.2 µM, 32.4µM and 64.8µM) and DHA (15.3 µM, 30.7µM and 
61.4µM). Thereafter, the assays were terminated by centrifugation (1200 rpm, 2 
minutes). The cells were washed in PBS (2 ml) followed by resuspension in lysis 
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buffer (1 ml/1×107 cells) and the samples stored at -20 ºC for batch analysis. The 
cellular survivin concentration without or upon test compound treatment was done by 
ELISA following the manufacturer’s instructions (R&D Systems Europe, Ltd., 
Abingdon, UK) with minor modifications. Briefly, the samples were thawed and 
centrifuged (1200 rpm, 5 minutes) and 80-90 µl of the supernatants transferred into 
clean eppendorff tubes. The samples were then diluted (1:2 dilutions) with assay 
diluent prior to the assay. Each of the wells were loaded with 100 µl 
samples/standard solutions and incubated for 2 h at room temperature. After 
incubation, each well was aspirated and washed three times with wash buffer, 
followed by the addition into each well of 100 µl of diluted Total Survivin Detection 
Antibody (1:15 dilution with reagent diluent) and incubating the plates for 2 h at room 
temperature. Then the wells were aspirated of the samples and washed three times 
with wash buffer. Thereafter, 100 µl diluted Streptavidin-HRP (1:200 dilutions) was 
added to each well and incubated for 20 minutes at room temperature, followed by 
three wash steps with wash buffer. Then, 100 µl of Substrate solution (1:1 substrate 
solution A and B) was added to each well and incubated for 20 minutes at room 
temperature, before 50 µl of Stop solution was added to each well and the plates 
read at 450 nm within 30 minutes. The concentration of cellular survivin without or 
upon test compound treatment was estimated from the standard curve using Grafit 
(Erithacus, UK).           
2.11. Effect of test compounds treatment on migration and invasion/wound 
healing 
For the wound healing assay, the cells were required to be confluent before a 
scratch (wound) is created. Here, HT29-AK cells (1×106 cells/well) were cultured in 
12-well flat-bottomed plates and incubated (37 °C, 5% CO2) without test compounds 
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for 5-7 days to allow the cells reach to confluency. A wound was created by using 
the tip of a sterile 10 µl pipette. This was followed by washing away of the non-
adherent cells with MEM media supplemented with 10% FBS three times. 
Thereafter, the cells were incubated (37 °C, 5% CO2) in absence and presence of 
LLP246 (1.1 µM, 2.2 µM and 4.5 µM); SL2935 (16.2 µM, 32.4 µM and 64.8 µM) and 
DHA (15.3 µM, 30.7 µM and 61.4 µM).  
In the case of the tetraoxane dimers, the cells were incubated in absence and 
presence of RKA152M (37.9 µM, 75.8 µM, 151.5 µM and 378.8 µM); RKA157 (34.4 
µM, 68.9 µM, 137.8 µM and 344.4 µM); RKA160 (11.4 µM, 22.8 µM, 45.7 µM and 
114.2 µM,) and DHA (30.7 µM, 61.4 µM, 122.9 µM and 306.9 µM).  
Following changes of the incubation media (every 2 days) the diameters of the 
wounds were measured under a light microscope at 10x magnification. This process 
was continued every 2 days for about 9 days. In order to reduce variability between 
measurements, a dot was applied under each well of the plates so that the diameter 
of same diameter area is measured every time. Photographs were taken using TS 
view so that we can compare test compounds-treated samples with control samples 
to enable the effect of test compounds treatment on wound closure to be assessed. 
2.12. Trypan blue test to evaluate cell death in the wound healing assay 
Here, an aliquot of the culture media was collected from each well (untreated and 
test compound-treated) prior to changing the incubation media and assayed for cell 
viability. Briefly, equal volumes of the collected samples and trypan blue dye were 
mixed before being loaded on the glass-slide and viewed under light microscope at 
10x magnification and pictures taken. Along with this, the numbers of dead cells 
were counted using a haemocytometer, following the equation: 
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Number of death cells/ml = average number of death cells in large corner square X 
1x104 cells/ml X 2       
2.13. Statistical analysis 
Data are expressed as mean ± SD; the Shapiro-Wilk test was used to assess the 
distribution of the data. Statistically significant differences between controls and test 
samples were then assessed either by one-way ANOVA followed by Mann-Whitney 
U test using StatsDirect statistical software, version 2.6.3, 2007 (Cheshire, UK). 
Significance between controls and test samples was assumed if P ≤ 0.05. 
2.14. Safety and ethical considerations 
Ethics exemption and COSHH forms were approved by Coventry University. Any 












Section 3  
                                                                                       Results 
3.1. Cytotoxicity of the test compounds against HT29-AK and HL-60 cells 
The cytotoxicity of the DNA intercalators, LLP246 and SL2935 and the tetraoxane 
dimers: RKA152M, RKA153, RKA154, RKA155, RKA157, RKA160 relative to DHA 
(parent compound) against HT29-AK and HL-60 cancer cells were evaluated using 
MTT assay. The compounds were cytotoxic against HT29-AK cell lines (table 2). 
LLP246 was significantly (P<0.001) more potent than DHA, with an IC50 of 4.47±0.39 
µM vs 61.39±2.86 µM. LLP246 displayed ~13.7 fold greater activity compared to 
DHA. In contrast, SL2935 was of similar cytotoxicity compared to DHA (table 2).  
Of the tetraoxane dimers, RKA160 was significantly (P<0.01) more cytotoxic than the 
parent drug DHA, being ~2.7 fold more potent than the parent compound DHA. All of 
the other tetraoxane dimers displayed only moderate cytotoxic activity against HT29-
AK cancer cells (table 2). The rank orders of potencies of the dimers are as follows: 
RKA160 > RKA157 > RKA152M > RKA154 > RKA155 > RKA153 (table 2). 
The tetraoxane dimers were evaluated for their in vitro activity against leukaemia-
derived HL-60 cancer cells relative to DHA as a control. The agents showed 
cytotoxic effects against the cells, but they were all significantly (P<0.001) less active 
compared to DHA (table 2). They showed the following rank orders of activity: 
RKA155 > RKA160 > RKA152M > RKA157 > RKA153 = RKA154 (table 2). The IC50 
of RKA153 and RKA154 compounds were greater than the highest concentration 




Table 2: The measured IC50 of the test compounds against HT29-AK and HL-60 cancer cells. Figures 
represent mean±SD of 3 separate experiments (n=3). **P<0.01 and ***P<0.001. ND-Not Determined 
Compounds HT29-AK                HL-60 
IC50 ± SD (µM) 
DHA 61.39±2.86 0.39±0.10 
LLP246 4.47±0.39*** ND 
SL2935 64.81±0.36 ND 
RKA152M 75.77±0.77 31.20±1.81 
RKA153 92.46±1.60 >100 
RKA154 77.58±5.46 >100 
RKA155 90.16±2.12 18.80±2.30 
RKA157 68.88±0.71 50.02±6.42 
RKA160 22.85±4.36** 20.17±2.37 
         
3.2. Test compound treatment altered the cellular concentration of sTfR in 
HT29-AK cells 
As iron is central to the cytotoxicity of the artemisinins, the effects of the test 
compounds on cellular sTfR levels were measured to give an indication of cellular 
transferrin levels and its relationship to the cytotoxic effects of the agents. Here, an 
investigation was made on the effects of test compounds treatment on cellular sTfR 
levels in HT29-AK cells. As can be seen in figure 3, the cells express sTfR (~8pg/ml), 
but the test agents showed variable effects. DHA at 15.3 µM and 30.7 µM had no 
effects on sTfR levels in the HT29-AK cells (figure 3A). However, DHA (at 61.4 µM) 
decreased sTfR concentration by ~1.3 fold (5.8 pg/ml) compared to control (7.8 
pg/ml). In contrast, LLP246 (at 4.5 µM) significantly (P<0.01) increased sTfR 
concentration, whereas no alterations in sTfR levels were measured at 1.1 µM and 
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2.2 µM of LLP246 (figure 3B). Similarly, treatment with SL2935 resulted in variable 
patterns of sTfR secretion, with 16.2 µM causing significantly (P<0.001) increased 
levels of sTfR, while 32.4 µM and 64.8 µM of SL2935 demonstrated no marked 




























































































































Figure 3: The effects of test compounds treatment upon the cellular concentration of sTfR in HT29-AK 
cells. Cells were treated with different concentrations of DHA, LLP246 and SL2935 as shown for 24 
hours before sTfR levels were measured by ELISA. A) Effects of 15.3 µM, 30.7 µM and 61.4 µM of 
DHA; B) Effects of 1.1 µM, 2.2 µM and 4.5 µM of LLP246 and C) Effects of 16.2 µM, 32.4 µM and 
64.8 µM of SL2935 on sTfR levels in HT29-AK cells. Results are the mean ± SD of three independent 






3.3. LLP246 and RKA compounds tested induced the release of catalytically 
active cleaved caspase-3 in HT29-AK and HL-60 cells, respectively 
The catalytically active cleaved caspase-3 levels were measured upon test 
compounds treatment to further investigate the mechanistic basis of LLP246-induced 
cell death. Compared to control, all of the DHA-treated cells showed a significant 
(P<0.001) increase in cleaved caspase-3 activity (figure 4A). There was a ~2.4 fold, 
~2.5 fold and ~2.6 fold increase in fluorescence upon treating cells with 15.3 µM, 
30.7 µM and 61.4 µM DHA, respectively (figure 4A). Similarly, LLP246 significantly 
(P≤0.05) induced an increase in the release of cleaved caspase-3 compared to 
control in HT29-AK cells. Control cells showed cleaved caspase-3 activity of 50.53 
RFU which was increased by ~2 fold (75.36 RFU) upon treating the cells with 4.5 µM 
LLP246 (figure 4B). 
The cleaved caspase-3 activity of HL-60 cells treated with tetraoxanes dimers was 
also measured. Compared to control, all of the DHA-treated cells showed a 
significant (P<0.001) concentration-dependent increase in cleaved caspase-3 activity 
(figure 4C). There was a ~2.6 fold, ~2.9 fold and ~3.2 fold increase in fluorescence 
upon treating the cells with 0.2 µM, 0.4 µM and 0.6 µM of DHA, respectively (figure 
4C). Similarly, RKA155 significantly (P≤0.001) induced an increase in catalytically 
active cleaved caspase-3 as compared to DHA in HL-60 cells. Control cells showed 
cleaved caspase-3 levels of 16.3 RFU which was increased by ~3.2 fold (52.63 RFU) 
upon treating the cells with 9.4 µM RKA155 (figure 4C). Similarly, treatment of cells 
with RKA160 (at all concentrations) resulted in significant (P<0.001) increase in 
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Figure 4: The effects of test compounds treatment on cleaved caspase-3 activity in HT29-AK cells. 
Cells were treated without and with different concentrations of LLP246 and DHA (as parent 
compound) for 24 hours before cleaved caspase-3 activity was measured by flow cytometric analysis. 
A) Effects of 15.3 µM, 30.7 µM and 61.4 µM of DHA; B) Effects of 1.1 µM, 2.2 µM and 4.5 µM of 
LLP246 on cleaved caspase-3 activity compared to control in HT29-AK cells; C) Effects of 0.2 µM, 0.4 
µM and 0.6 µM of DHA; 9.4 µM, 18.8 µM and 28.2 µM of RKA155 and 10.1 µM, 20.1 µM and 30.3 µM 
of RKA160 on cleaved caspase-3 activity in HL-60 cells.. Results are the mean ±SD of three 





3.4. Test compounds treatment increased the cellular levels of AKT in HT29-AK 
cells 
Compared to control (29.06 RFU), DHA treatment increased P-AKT activity by ~1.6 
fold (45.59 RFU), ~1.7 fold (50.52 RFU) and ~1.8 fold (52.26 RFU) upon treating the 
HT29-AK cells with 15.3 µM, 30.7 µM and 61.4 µM of DHA, respectively (figure 5A). 
Similarly, LLP246 caused a significant (P≤0.05) increase in the activity of P-AKT as 
compared to control in HT29-AK cells (figure 5B). Here, control cells showed P-AKT 
activity of 45.75 RFU which was increased ~1.1 fold (49.66 RFU), ~1.4 fold (63.51 
RFU) and ~1.6 fold (75.27 RFU) upon treating the cells with 1.1 µM, 2.2 µM and 4.5 














































































Figure 5: The effects of test compounds treatment upon the cellular levels of P-AKT in HT29-AK cells. 
Cells were treated without and with different concentrations of LLP246 and DHA (as control) for 24 
hours before the P-AKT activity was measured by flow cytometric analysis. A) Effects of 15.3 µM, 
30.7 µM and 61.4 µM of DHA and B) Effects of 1.1 µM, 2.2 µM and 4.5 µM of LLP246 on the levels of 
P-AKT. Results are the mean ±SD of three independent experiments (n=3). *P<0.05 and **P<0.01 as 





3.5. DHA, LLP246 and SL2935 induced DNA fragmentation in HT29-AK cells 
The analyses of induction of DNA fragmentation in HT29-AK cells was evaluated 
after incubating the cells with and without the test compounds for 24 h. As can be 
seen in figure 6, the drugs caused DNA damage which is illustrated in all the lanes 
by smearing. The effects of DHA on DNA damage was detectable in lanes 1, 2 and 3 
which were treated with 61.4 µM, 30.7 µM and 15.3 µM of DHA, respectively. 
Similarly, the effects of LLP246 on DNA damage was detectable in lanes 4, 5 and 6 
which were treated with 4.5 µM, 2.2 µM and 1.1 µM of LLP246. SL2935 treatment 
also caused DNA damage in lanes 7, 8 and 9 which were treated with 64.8 µM, 32.4 
µM and 16.2 µM SL2935, respectively.  
 
 
Figure 6: A representative image showing the effect of drug treatment on DNA fragmentation using 
agarose gel electrophoresis. HT29-AK cells were exposed to different concentrations of the test 
compounds for 24 hours. Purified DNA from control, heat treated and drug-treated samples were 
separated on 1.0 % agarose gel and visualized under UV light. Lamda Eco 1301 Molecular marker 
ladder (Bioline, UK) was used to determine DNA bands from 421 kDa to 19329 kDa, as shown in lane 
labelled Mwm. Lane 1=61.4 µM, lane 2=30.4 µM and lane 3=15.3 µM DHA-treated samples; lane 
4=4.5 µM, lane 5=2.2 µM and lane 6= 1.1 µM LLP246-treated samples; lane 7=64.8 µM, lane 8=32.4 
µM and lane 9=16.2 µM SL2935-treated samples, respectively. Lane 10 is control and lane 11 is a 
heat- treated control. 
 
The characteristics DNA smear pattern in all the above mentioned lanes at different 
concentrations of the respective test compounds represent degradation of genomic 
DNA into smaller, low molecular weight fragments being definitive signs of induction 
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of apoptosis. Because different amounts of DNA were inadvertently added into each 
well (due to operator error), it is not possible to visualise the concentration-
dependent effects of the test compounds on DNA damage. However, despite this, it 
can be observed that compared to control (lane 10) and heat-treated samples (lane 
11), treatment of the cells with the test compounds caused observable DNA damage 
(figure 6).   
3.6. Test compounds treatment decreased cellular survivin levels in HT29-AK 
cells 
Given that survivin plays a pivotal role in the regulation of apoptosis, the effects of 
our novel agents on this unique molecule were investigated. As can be seen in figure 
7A, DHA (at 15.3 µM and 30.7 µM) of the concentrations tested, significantly 
(P<0.05) decreased survivin concentration. In contrast, no alteration in the levels of 
survivin was observed upon treating the cells with any of the concentrations used of 
LLP246 (figure 7B). However, there was a significant (P ≤ 0.05) in survivin 
concentration in HT29-AK cells, with a ~1.4 fold (4233.3 pg/ml) and ~2.7 fold (2128.3 
pg/ml) decrease in levels as compared to control samples (5816.6 pg/ml) upon 




























































































































Figure 7: Showing the effects of test compounds treatment upon cellular survivin levels in HT29-AK 
cells. Cells were treated with different concentrations of DHA, LLP246 and SL2935 as shown for 24 
hours before survivin levels were measured by ELISA. A) Effects of 15.3 µM, 30.7 µM and 61.4 µM of 
DHA; B) Effects of 1.1 µM, 2.2 µM and 4.5 µM of LLP246 and C) Effects of 16.2 µM, 32.4 µM and 
64.8 µM of SL2935 on survivin levels in HT29-AK cells. Results are the mean ± SD of three 
independent experiments (n=3). *P<0.05, **P<0.01 and ***P<0.001 as tested by the Mann-Whitney U 
test. 
 
3.7. Test compounds treatment caused an inhibition of the capacity of the 
wound to heal in HT29-AK cells  
To investigate the effects of test compounds on the migration/invasion of cells, the 
effects on wound healing were measured. Upon the cells reaching confluency (figure 
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8X) after 7 days a wound was created (figure 8Y) using the tip of sterile 10 µl pipette 
and the cells were treated without or with the test compounds as shown (figure 8A-I). 
It was observed that the wound in figure 8Y with diameter of 64.14 µm (figure 10) 
was closed after 9 days as shown in figure 8Z, while there is concentration-
dependent inhibition of the ability of the wound to heal/close (figure 8A, B and C) 
upon treatment with DHA (at 30.7 µM, 61.4 µM and 122.8 µM, respectively) after 9 














   
   
   
   
Figure 8: Representative light-microscopic images of the concentration-dependent effects of the test 
compounds (DHA, LLP246 and SL2935) on wound healing in HT29-AK cells. Cells were cultured for 7 
days to allow the establishment of confluency (X) and following the creation of a scratch (wound) 
using the tip of a sterile 10 µl pipette (Y). (Z) Shows the closure of the wound created in Y following 7 
days of culture without test compound treatment. This serves as the positive control. Effects of A) 
30.7 µM, B) 61.4 µM and C) 122.8 µM of DHA. Effects of D) 2.2 µM E) 4.5 µM and F) 9.0 µM of 
LLP246. Effects of G) 32.4 µM, H) 64.8 µM and I) 129.6 µM of SL2935 on wound healing in HT29-AK 
cells after 9 days. Lines represents the wound area, which can be seen to have closed or widened in  
the images. Images are at 10x magnification. 
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There was also a concentration dependent inhibition of wound healing with diameter 
of 23.42 µm, 47.06 µm and 53.57 µm, respectively (figure 10) following treatment 
with LLP246 (at 2.2 µM, 4.5 µM and 9.0 µM, respectively) (figure 8D, E and F). 
Similarly, upon treatment with SL2935 (at 32.4 µM, 64.8 µM and 129.6 µM), there 
was a concentration-dependent inhibition of wound healing with diameter of 22.10 
µm, 44.90 µm and 71.33 µm, respectively, after 9 days of culture (figure 8G, H and I; 
figure 10).     
Given that the tetraoxane dimers showed cytotoxic activity, their effects on wound 
healing in comparison to DHA were investigated. Upon the cells reaching confluency 
(figure 9X) after 7 days a wound was created (figure 9Y). After washing away the 
non-adherent cells, the plates were treated without or with the test compounds as 
shown (figure 9A-P). It was observed that the wound with diameter 50 µm (figure 11) 
in figure 9Y was almost closed with wound diameter 5 µm (figure 11) after 9 days of 
culture as shown in figure 9Z. There is concentration-dependent inhibition of the 
ability of the wound to heal/close after 9 days of culture with DHA (at 30.7 µM, 61.4 
µM and 122.8 µM, respectively) with diameter of 18.2 µm, 10.43 µm and 28.14 µm, 
respectively (figure 9A, B and C; figure 11); RKA152M (at 37.9 µM, 75.8 µM and 
151.5 µM, respectively) with diameter of 21.01 µm, 36.86 µm and 86.87 µm, 
respectively (figure 9E, F and G; figure 11); RKA157 (at 34.4 µM, 68.9 µM and 137.8 
µM, respectively) with diameter of 44.29 µm, 42.28 µm and 58.3 µm, respectively 
(figure 9I, J and K; figure 11) and RKA160 (at 11.4 µM, 22.8 µM and 45.7 µM 
respectively) with diameter of 10.29 µm, 24.14 µm and 44.86 µm, respectively (figure 









    
   
 
Figure 9: Representative light-microscopic images of the concentration-dependent effects of the test 
compounds (DHA, RKA152M, RKA157 and RKA160) on wound healing in HT29-AK cells. Cells were 
cultured for 7 days to allow the establishment of confluency (X) and following the creation of a wound 
using the tip of a sterile 10 µl pipette (Y). (Z) Shows the closure of the wound created in Y following 9 
days of culture without drug treatment. This serves as the positive control. Effects of A) 30.7 µM, B) 
61.4 µM, C) 122.8 µM and D) 306.9 µM of DHA. Effects of E) 37.9 µM, F) 75.8 µM G) 151.5 µM and 
H) 378.8 µM of RKA152M. Effects of I) 34.4 µM, J) 68.9 µM, K) 137.8 µM and l) 344.4 µM of RKA157. 
Effects of M) 11.4 µM, N) 22.8 µM, O) 45.7 µM and P) 114.2 µM of RKA160 on wound healing in 
HT29-AK cells after 9 days. Lines represent the wound area, which can be seen to have closed or 
widened in the images. Arrows shown in images H, L and P illustrate that the wound sizes are greater 
than the margin of the images. Images are at 10x magnification. 
 
It was observed that at the highest concentration of each test compound a much 
larger wound than that created in the control (figure 9Y) was left due to the 
[42] 
 
cytotoxicity of the agents, with DHA at 306.9 µM, RKA152M at 378.8 µM, RKA157 at 
344.4 µM and RKA160 at 114.2 µM  (figure 9 and 11).  Overall, the RKA compounds 















































































































Number of dead cells/ml (1x10e4)
 
 
Figure 10: The graph showing effects of test compounds treatment on the capacity of 
the wound to heal via means of diameters and viability on HT29-AK cells.  Cells were 
allowed to reach confluency before a scratch (wound) is created and the cells then 
treated without or with different concentrations of DHA: 30.7 µM, 61.4 µM and 122.8 
µM; LLP246: 2.2 µM, 4.5 µM and 9.0 µM; SL2935: 32.4 µM, 64.8 µM and 129.6 µM 
for 9 days. Following incubation, the diameters of the wounds were estimated as 




































































































































































Number of dead cells/ml (1x10e4)
 
Figure 11: The graph showing effects of test compounds treatment on the capacity of the 
wound to heal via means of diameters and viability on HT29-AK cells.  Cells were allowed to 
reach confluency before a scratch (wound) is created and the cells then treated without or 
with different concentrations of DHA: 30.7 µM, 61.4 µM and 122.8 µM; RKA152M: 37.9 µM, 
75.8 µM and 151.5 µM; RKA157: 34.4 µM, 68.9 µM and 137.8 µM; RKA160: 11.4 µM, 22.8 
µM and 45.7 µM for 9 days. Following incubation, the diameters of the wounds were 
estimated as described in the materials and methods section.  
 
3.8. Trypan blue dye exclusion to test for viability 
As the test compounds are shown to be cytotoxic (table 2) and also decreased the 
ability of the wound to close (figure 8 and 9), further studies were conducted to find 
out if the cells that can be seen in the vicinity of the wounds in figure 8 and 9 were 
dead or live cells, i.e. whether these was some migrations of the cells. Here, an 
aliquot of the cell suspension from each of the respective wells was stained with 
trypan blue and the results of this manipulation can be seen in figure 10 and 11. 
There was a concentration-dependent increase in the number of dead cells 




Figure 12: Representative light-microscopic images of the concentration-dependent effect of 
the test compounds (DHA, LLP246 and SL2935) on the viability of HT29-AK cells. (Z) 
Represents control which is used to compare test compound-treated samples. Effects of A) 
15.3 µM, B) 30.7 µM and C) 61.4 µM of DHA. Effects of D) 1.1 µM, E) 2.2 µM and F) 4.5 µM 
of LLP246. Effects of G) 16.2 µM, H) 32.4 µM and I) 64.8 µM of SL2935 on HT29-AK cells. 
An aliquot of the cell suspension in figure 8 was taken from each well and stained with 
trypan blue. Arrows represent dead cells with dark blue colour and live cells with bright 
colour. Similar data were obtained for the cells treated with the tetraoxane dimers. Images 
are at 10x magnification. 
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As can be seen in figure 10, there is concentration dependent increase in dead cells 
with 10 x 106, 16 x 106 and 29 x 106 cells/ml with DHA 30.7 µM, 61.4 µM and 122.8 
µM treatment; 22 x 106, 103 x 106 and 150 x 106 cells/ml with LLP246 2.2 µM, 4.5 
µM and 9.0 µM treatment; 20 x 106, 98 x 106 and 269 x 106 cells/ml with SL2935 
32.4 µM, 64.8 µM and 129.6 µM treatment, respectively, compared to control (2 x 
106 cells/ml) in suspension. These results were supported by images captured under 
light microscope (figure 12); showing the concentration-dependent increase in 
number of dead cells in suspension as compared to control (figure 12Z).   
As can be seen in figure 11, all of the test compounds increased cell death in a 
concentration-dependent manner with RKA152M having the greatest effects. In case 
of RKA160, the numbers of dead cells were similar to that of DHA (figure 11). The 
rank order for the number of dead cells with respect to test compound used is: 
RKA157<RKA160=DHA<RKA152M. Despite this, it can be seen that the test 
compounds did not inhibit some of the cells from migrating into the vicinity of the 










Section 4  
                                                                                  Discussion 
The ARSs have already shown great potential as anti-cancer agents in vitro and in 
vivo (Chen et al., 2004; Efferth, 2007; Soomro et al., 2011). These compounds have 
been extensively studied as promising candidates for cancer therapy (Efferth, 2005; 
Mercer et al., 2007; Lu et al., 2008) and owing to their structure being amenable to 
modification. Rational drug design and synthesis are well-established disciplines in 
pharmaceutical research. The endoperoxides have been shown to  possess potent 
cytotoxic activity against human colon and leukaemia cancer cells (Mercer et al., 
2007; Jones et al., 2009). In contrast, the agents are lowly cytotoxic against human 
non-small lung neoplastic cells which depend on the lower proliferative and iron 
uptake status compared to the former cells types (Efferth, 2005; Mercer et al., 2007).  
The current study aimed at investigating the cytotoxicity and mode of action of 
rationally designed novel compounds based on the ARS backbone. In study by 
Mercer et al, it was demonstrated that ARS derivatives such as deoxy-10beta-(-P-
flourophenoxy) DHA, which lacks the endoperoxide bridge, was 50- and 130-fold 
less active in HL-60 and Jurkat cells by using liquid chromatography-mass 
spectrometery analyses to monitor endoperoxide activation (Mercer et al., 2007). 
Given that the presence of the endoperoxide bridge is important for antitumour 
activity, it was investigated whether the presence of more –C-O-O-C in the structure 
would result in improved activity. To this end, the activity of tetraoxane dimers was 
investigated against the cells. Our initial studies investigated the cytotoxicity of 
LLP246, SL2935 (derivatives of DHA, rationally designed from DHA and dipyrrole) 
against HT29-AK. In addition, the activity of tetraoxane dimers (RKA 152M, RKA 
[47] 
 
153, RKA 154, RKA 155, RKA 157 and RKA 160) were evaluated against HT29-AK 
and HL-60.  
It was observed that LLP246 (with an IC50 of 4.47±0.39 µM) is significantly (P<0.001) 
more potent than DHA (IC50 of 61.39±2.86 µM), whereas, SL2935 (IC50 of 64.81±0.36 
µM) is of identical potency to DHA against HT29-AK cells. The improved cytotoxicity 
of LLP246 over DHA may be due to the presence of the acridine moiety within the 
structure. There is evidence that 1,2,4-trioxanes interact with DNA (Jones et al., 
2009) and this may be further enhanced by the acridine skeleton, making LLP246 
even more DNA-selective thus cytotoxicity (Baraldi et al., 2003; Baraldi et al., 2006; 
Jones et al., 2009). Furthermore, several in vitro studies suggest that 1,2,4-trioxanes 
growth inhibition activities against tumour cells are associated with cell-cycle 
obstruction (Mercer et al., 2007; Parekh et al., 2009; Zhang et al., 2010). It has been 
reported that DHA and its ether-linked dimers inhibit cell cycle progression through 
G1 phase arrest by accumulation of cancer cells in G1 phase and up-regulation of 
GADD 153, which is an ER-stress molecule (Efferth, 2005; Mercer et al., 2007; Lu et 
al., 2010). It is reasonable to postulate that LLP246 may interfere with cell-cycle 
progression which ultimately results in growth inhibition.  
Although, 1,2,4,5-tetraoxanes have demonstrated inhibition of cancer cell 
proliferation at micromolar and submicromolar levels through an apoptotic 
mechanism (Zizak et al., 2009; Kumar, Sharma and Rawat, 2011), it was observed 
that dimerization of the tetraoxanes did not enhance their anti-tumour effects against 
the cell types studied. Of the tetraoxane dimers evaluated, RKA 160 (IC50 of 
22.85±4.36 µM) is the most potent, being 2.7 times more potent than DHA against 
HT29-AK cell line (table 2). In contrast, none of the other dimers were as potent as 
DHA (IC50 of 0.39±0.10 µM) against HL-60 cells (table 2). The endoperoxide bridge 
[48] 
 
is central to antimalarial and antitumour activity (Mercer et al., 2007). Evidence in 
support of this stems from the observation that oral co-administration of ART with 
ferrous sulphate resulted in greater cytotoxicity compared to ART alone (Fafowora et 
al., 2011). Similarly, iron tagged artemisinins demonstrated improved cytotoxic 
activity over artemisinin alone (Singh and Lai, 2001; Lai et al., 2005). Following these 
findings, It can be hypothesised that the presence of more endoperoxide bridges 
does not necessarily translate into greater cytotoxicity (figure 2C-H). This may be 
due to the unavailability of sufficient cellular iron to reductively cleave all of the 
peroxide bridges, generating the carbon-centred radicals which ultimately kill the 
cells. Alternatively, it may be due to the reduced capacity of these agents to enter 
the cells, due to steric hindrance. Future experiments may confirm these findings by 
tagging the test compounds with transferrin or evaluating their effects in the 
presence of ferrous sulphate. 
Iron is an important co-factor for DNA metabolism and cancer cells need to take it up 
via TfR for growth and proliferation (Mercer et al., 2007; Oh et al., 2009). Thus, TfR 
expression is increased to facilitate iron intake, and its increased expression 
positively correlates with the aggressiveness of cancer cells (Efferth, 2005; Singh 
and Lai, 2006; Cheung et al., 2010). There is a positive correlation between total TfR 
and sTfR; thus concentration of sTfR is an indirect measure of TfR levels (Beguin et 
al., 1988; Singh and Lai, 2001; Lai et al., 2005). In other words, the measurement of 
sTfR is not only valuable in determining prognosis but also in indirectly assessing the 
cellular levels of iron (Ferguson et al., 1992; Erslev and Besarab, 1995), which is 
important in linking the antitumour effects of the agents. In the current study, the 
measured sTfR in both control and test compounds treated samples suggest the 
presence of iron in the cells. DHA decreased, in a concentration-dependent manner, 
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the levels of sTfR as compared to untreated HT29-AK cancer cells (figure 3A). In 
contrast, LLP246 and SL2935 demonstrated variable effects on sTfR (figure 3B and 
3C). It warrants further investigating in order to decipher the true effects of the test 
compounds on sTfR levels. Overall, our data show the presence of sTfR which 
confirms the presence of iron within the cells and hence the observed cytotoxic 
effects of the test compounds (table 2).  
Many studies have shown that some anticancer agents prevent tumour promotion 
and progression via the induction of apoptosis (Huang et al., 2006; Mercer et al., 
2007; Handrick et al., 2010; Morrissey et al., 2010). Apoptosis is initiated by the 
induction of caspase-dependent apoptotic cell death, mitochondrial endoplasmic 
reticulum stress, activation of effector caspases-3 and -7, induction of cell cycle 
arrest at GO/G1 phase and subsequent DNA fragmentation (Parekh et al., 2009; 
Zhang, Chen and Gerhard, 2010; Morrissey et al., 2010; Alessandro et al., 2011). 
Caspase-3 is involved in both intrinsic and extrinsic pathways (Ghavami et al., 2010). 
It has been reported that DHA induces apoptosis by up-regulation of pro-apoptotic 
protein Bax in pancreatic cancer cells leading to the downstream activation of 
caspase-3, a major final stage in the apoptotic pathway, causing apoptosis (Aung et 
al., 2011). In addition, DHA induced caspase-dependent apoptotic cell death 
characterised by mitochondrial membrane depolarisation, activation of caspase-3 
and -7, sub-G0/G1 DNA formation all of which were attenuated by treatment with 
benzyloxycarbonyl-VAD-fluoromethyl ketone, a caspase inhibitor (Efferth, 2006; Jiao 
et al., 2007, Lu et al., 2009). In human leukaemia HL-60 and HT29-AK cells, DHA 
induced apoptosis, which was associated with mitochondrial dysfunction and 
caspase-3 activation in a concentration-dependent manner (Li et al., 2007; Lu et al., 
2008; Zhou et al., 2008; Jones et al., 2009). Data shown here demonstrate that DHA 
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and LLP246 elevated the levels of catalytically active caspase-3 in HT29-AK cell line 
(figure 4A and 4B). It is also demonstrated the tetraoxane dimers, RKA155 and 
RKA160 also elevated the levels of catalytically active caspase-3 in HL-60 cells 
(figure 4C). It may be postulated that the agents increase in cellular caspase-3 may 
cause the activation of death receptor DR5, initiator (apical) caspase-8, which will 
trigger activation of effector caspases -3, but also caspase 6 and 7 which may lead 
to DNA fragmentation and ultimately apoptosis (Mercer et al., 2007; Lu et al., 2008; 
Ghavami et al., 2009; Lu et al., 2009; He at al., 2010). Although there was no 
evidence to suggest the involvement of either the intrinsic or/and extrinsic pathway in 
the increased levels of cleaved caspase-3, there is evidence that the intrinsic 
pathway (mitochondrial) may be initiated by several different stimuli, such as extra- 
or intracellular stress signals or upon drug therapy (Efferth, 2005; Ghavami et al., 
2009), it is probable that LLP246 treatment may be the activator of the pathway.  
Data presented here suggest that test compounds treatment of the cells caused 
DNA fragmentation (figure 6). There were signs of DNA fragmentation in HT29-AK 
cells upon DHA, LLP246 and SL2935 treatment as compared to untreated samples 
(figure 6). The cytotoxicity of the agents may be explained by their effects on 
caspase-3 activity leading to DNA fragmentation and ultimately apoptosis (Efferth, 
2005; Lu et al., 2009; He et al., 2010).  
AKT promotes cell survival, proliferation and plays a vital role in a number of cell 
signalling pathways, regulating pro-survival genes in many cancers (O’Gorman et al., 
2000; De Souza, Russell and Kearsley, 2009). An in-vitro study in human prostate 
malignant cells (PC-3, DU145 and LNCaP) has shown DHA-mediated apoptosis with 
the inhibition of the PI3-Kinase/AKT pathway and extracellular signal regulated 
kinase survival pathway (He et al., 2010). Here, a concentration- dependent increase 
[51] 
 
in levels of P-AKT in HT29-AK cells upon both LLP246 and DHA treatment was 
measured (figure 5). Previous studies have demonstrated that PI3K/AKT pathway 
controls cell survival and drug resistance in HT29-AK and in drug resistant 
HT29RDB colon cancer cells (Ghani et al., 2006; Chen, 2011). It can be speculated 
that the increase in P-AKT levels may be due to a reciprocal attempt of the cells to 
survive upon treatment of the agents or as independent stimuli to inhibit apoptosis 
induced upon test compounds treatment. It has been suggested that increase in P-
AKT may involve mitogen signalling pathways mediated by Ras and PI3K/AKT in 
controlling multidrug resistance in colon cancer cells (Ghani et al., 2006). Further 
studies 9in the presence and absence of PI3K/AKT inhibitors) would clarify the role 
of P-AKT in the cytotoxicity of the test compounds.  
Survivin is over expressed in human malignancies including colorectal cancer and 
leukaemia, but rarely in healthy tissues and its down regulation may have a crucial 
role in cancer drug therapy (Lu, Luo and Tao, 2007; Ryan, O’Donovan and Duffy, 
2009; Liu et al., 2010). Previous study in 4 prostate cancer cell lines (C4-2, LNCaP, 
DU145 and PC-3) showed that ARS dimer (2PY) at 15µM significantly decreased the 
expression of survivin at the mRNA levels (Morrissey et al., 2010). It is known that in 
tumourigenesis, survivin expression is inversely correlated with inhibition of 
apoptosis (Lu et al., 2005; Ryan, O’Donovan and Duffy, 2009). Data reported here 
suggest a dysregulation of the cells ability to regulate apoptosis. There was a 
concentration-dependent decrease in levels of survivin upon SL2935 treatment 
(figure 7C). DHA and LLP246 also decreased survivin levels but this was not 
concentration-dependent (figure 7A and 7B). It can be speculated that the higher 
concentration of test compound did not cause any further drop in survivin levels 
because there may be a threshold beyond which no further drop can occur.  
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Metastasis and invasion are fundamental properties of malignant cancer cells which 
is a leading cause of death in patients with cancer (Hwang et al., 2010). ARS has a 
concentration-dependent inhibitory effect on invasion and migration in human 
carcinoma cell lines HepG2 and SMMC-7721, both in vitro and in vivo (Du et al., 
2009; Weifeng et al., 2011). DHA is also an effective anti-metastastic agent against 
human fibrosarcoma HT-1080 cells (Hwang et al., 2010; Wang et al., 2011). The 
scratch (wound healing) model used in our studies confirms these findings in HT29-
AK cells. A concentration-dependent inhibition of wound healing upon treating HT29-
AK cells with DHA, LLP246, SL2935 and RKA compounds as compared to untreated 
samples, demonstrated by an increase in wound diameter was measured (figure 8-
11). The wound healing results were also supported by the trypan blue test, which 
showed a concentration-dependent increase in dead HT29-AK cells as compared to 
control (figure10-12). In previous studies inhibition of MMP expression or enzyme 
activity can be used as early targets for preventing cancer metastasis (Liabakk, 
1996; Wang et al., 2011). It can be postulated that these compounds cause 
decreased capacity of the wounds to close via down-regulation of MMP-9, MMP-2 
gene expression, through inhibition of PKCa/Raf/ERK and JNK phosphorylation, 
reduction of NF-kB and activation of Cdc42, which enhanced E-cadherin activity, 
resulting in greater cell-cell adhesion and consequently reduced metastasis. Further 
experiments, such as testing the effects of the test compounds on the expression of 
MMP-9 and MMP-2, which are the focus of current investigations, may accept or 
refute these claims.  
Conclusions: The rationally designed and synthesised novel agents showed potent 
cytotoxic effects against HT29-AK and HL-60 cells. There is evidence of the 
presence of TfR, stemming from the measurement of sTfR in the samples. The 
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cytotoxicity of the test compounds is strongly mediated by increased levels of 
caspase-3, DNA fragmentation, decreased survivin levels and an inability of the 
wound to close. The results presented here provide evidence that further studies of 
test compounds may have cytotoxic activity (either alone or in combination with 
conventional chemotherapeutic agents) against other cancer cell types, such as 
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